[144] Quest Diagnostics Inc. SEC Filing

Rhea-AI Filing Summary

Quest Diagnostics (DGX) Form 144 notice shows a proposed sale of 72 shares of common stock through Fidelity Brokerage (approximate aggregate market value $12,960.00) with an approximate date of sale of 08/15/2025. The filer reports prior acquisitions via the company's ESPP: 12 shares acquired 01/31/2022 and 60 shares acquired 07/19/2024, both paid in cash. The filing also discloses a recent sale by Thomas P. Plewman of 5,535 shares on 08/06/2025 for gross proceeds of $968,625.00. The notice includes the standard representation that the seller is not aware of undisclosed material adverse information and references trading-plan/Rule 10b5-1 provisions but does not state a plan adoption date.

Positive

• Disclosure compliance: The filer submitted a Form 144 detailing the proposed sale, acquisition history, and recent insider transactions, meeting Rule 144 notice requirements.
• Small proposed sale: The current filing shows a proposed sale of only 72 shares, a modest amount relative to the previously reported sale.

Negative

• Recent large insider sale: Thomas P. Plewman sold 5,535 shares on 08/06/2025 for gross proceeds of $968,625.00, which may draw investor scrutiny.
• No 10b5-1 plan date provided: The filing references trading-plan provisions but does not state a plan adoption date, reducing clarity on whether sales were pre-planned.

Insights

Securities Analyst

TL;DR: Small planned sale (72 shares) contrasts with a recent larger insider sale (5,535 shares for $968,625), which may attract investor attention.

The Form 144 documents a modest proposed disposition of 72 shares via Fidelity with an indicated aggregate market value of $12,960.00 and confirms prior ESPP purchases totaling 72 shares. Separately, a substantial sale by Thomas P. Plewman on 08/06/2025 of 5,535 shares for $968,625.00 is reported as securities sold during the past three months. From a trading-volume perspective the 5,535-share sale is materially larger than the current proposed sale and represents concrete insider liquidity. The filing contains no earnings, operational updates, or statements of intent for proceeds, so economic interpretation should be limited to disclosure of trading activity.

Corporate Governance Expert

TL;DR: Disclosure is compliant but lacks any stated 10b5-1 plan date; recent insider sale may prompt governance questions.

The document fulfills Rule 144 notice requirements by listing the securities to be sold, acquisition history via ESPP, and recent insider sales. It includes the customary certification that no undisclosed material adverse information exists. The form does not indicate a Rule 10b5-1 plan adoption date or other trading-plan details, which would clarify whether sales were pre-planned versus discretionary. For governance transparency, investors often prefer explicit plan dates; their absence limits interpretability of insider intent.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	72	12960.00	111823441	08/15/2025	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	01/31/2022	ESPP Purchase	Issuer			12	01/31/2022	Cash
Common	07/19/2024	ESPP Purchase	Issuer			60	07/19/2024	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Thomas P. Plewman 500 Plaza Drive Secaucus NJ 07094	Common	08/06/2025	5535	968625.00

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Quest Diagnostics' (DGX) Form 144 report?

The Form 144 reports a proposed sale of 72 shares (aggregate market value $12,960.00) with an approximate sale date of 08/15/2025, acquisition history via ESPP, and a prior sale of 5,535 shares on 08/06/2025 for $968,625.00.

Who executed the recent large sale disclosed in the filing?

The filing lists Thomas P. Plewman as the seller of 5,535 shares on 08/06/2025 for gross proceeds of $968,625.00.

Were the shares being sold originally acquired through an employee plan?

Yes. The filer reports acquiring shares via the company ESPP: 12 shares on 01/31/2022 and 60 shares on 07/19/2024, paid in cash.

Does the Form 144 state a Rule 10b5-1 trading plan adoption date?

No. The filing references trading-plan/Rule 10b5-1 provisions but does not provide a plan adoption or instruction date.

Through which broker will the proposed 72-share sale be executed?

The proposed sale lists Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield RI 02917 as the broker.